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Background:Early diagnosis of hepatitis C virus (HCV) infection is essential to allowappropriate treatment
and prevent transmission.
Objectives: To evaluate the Elecsys® Anti-HCV II assay as a routine screening assay in Asia using a large
number of samples fromdifferent Asian Paciﬁc populations and compare its performancewith other HCV
assays routinely used in the region.
Abbreviations: EIA, enzyme immunoassay; HCV, hepatitis C virus; HIV, human immunodeﬁciency virus; Indet, indeterminate; N/A, not available; NEG, negative; NT, not
tested; PCR, polymerase chain reaction; POS, positive; RNA, ribonucleic acid; RR, repeatedly reactive; s/co, signal to cut-off.
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Study design: The sensitivity and speciﬁcity of the Elecsys® Anti-HCV II assay were determined using
routine hospital samples and compared with at least one of the following comparator assays at nine
independent centers: ARCHITECTTM Anti-HCV; Serodia®-HCV Particle Agglutination; Vitros® ECi Anti-
HCV; Elecsys® Anti-HCV; ADVIA Centaur® HCV; InTec® HCV EIA; or Livzon® Anti-HCV. Commercially
available seroconversion panels were used to assess sensitivity for early detection of infection.
Results: The Elecsys® Anti-HCV II assay was more sensitive in recognizing early infection and detected
acute HCV infection earlier on average than the comparator assays for all six panels tested. 7,726 routine
sampleswere tested and 322 identiﬁed as HCV positive. Elecsys® Anti-HCV II had a sensitivity of 100% and
a speciﬁcity of 99.66%, both of which were comparable or superior to the results obtained for competitor
assays, which ranged from 87.5–100% and 98.98–100%, respectively.
Conclusions:TheElecsys® Anti-HCV II assayhas the sensitivity and speciﬁcity to support its use as a routine
screening method in the Asia Paciﬁc region. Furthermore, this assay shortens the diagnostic window
between infection and the detection of antibodies compared with established methods.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Background
Hepatitis C virus (HCV) infection is a global health burden;
approximately 170 million people are chronically infected world-
wide and HCV-related liver disease is responsible for over 250,000
deaths annually [1,2]. Over 50% of all HCV-positive individuals live
in the Asia Paciﬁc region where prevalence rates range from 1.0%
in Singapore to 5.5% and 5.6% in Taiwan and Thailand, respectively,
and 15.6% in Mongolia [3–6]. An estimated 83 million people living
in the Asia Paciﬁc region and 400,000 in Australia and Oceania are
chronically infected with HCV [3].
As there is currently no vaccine against the infection, prevention
of transmission relies on the diagnosis, appropriate education and
treatment of infected individuals. However, many patients remain
undiagnosed [7], partly due to the asymptomatic nature of most
chronic infections. Once the infection has been diagnosed it can
be successfully treated in most cases with peginterferon and rib-
avirin [5,8]. There have also been several advancements in HCV
therapy over recent years, with the licensing of boceprevir and
telaprevir in 2011, and more recently of simeprevir and sofosbuvir
[9–12].
In many clinical laboratories anti-HCV assays remain the ﬁrst
choice for testing samples for HCV infection. Anti-HCV assays
have evolved and those currently available detect infection ear-
lier and have improved sensitivity and speciﬁcity compared with
older generation assays [2,13]. The Elecsys® Anti-HCV II assay
(Roche Diagnostics GmbH, Penzberg, Germany) was developed
to offer enhanced seroconversion sensitivity, speciﬁcity and con-
venience over the Elecsys® Anti-HCV assay. It is a qualitative
electro-chemiluminescence immunoassay and uses recombinant
antigens and syntheticpeptides, labeled core,NS3andNS4antigens
to detect HCV antibodies in the sample [14,15]. The performance of
the Elecsys® Anti-HCV II assay was established by a CE evaluation
study comparing the two Elecsys® assays with other commercially
available anti-HCV assays in routine clinical use and as a result it is
CE approved for diagnostic use and for screening blood donations
[14].
2. Objectives
To evaluate the Elecsys® Anti-HCV II assay as a routine screen-
ing assay in Asia using a large number of samples from different
Asian Paciﬁc populations. We also aimed to compare its perfor-
mance with that of other HCV assays routinely used in the region
and to verify the initial sensitivity and speciﬁcity ﬁndings for the
assay.
3. Study Design
3.1. Centers and assays compared
The study was performed at nine independent centers as
shown in Table 1. Each tested the Elecsys® Anti-HCV II assay
[15] and at least one comparator assay: ARCHITECTTM Anti-HCV
(Abbott Laboratories, Wiesbaden, Germany) [16]; Serodia®-HCV
Particle Agglutination (Fujirebio, Tokyo, Japan) [17]; Vitros® ECi
Anti-HCV (Ortho Clinical Diagnostics, High Wycombe, UK) [18];
Elecsys® Anti-HCV (Roche Diagnostics, Penzberg, Germany) [19];
ADVIA Centaur® HCV (Siemens Healthcare Diagnostics, Marburg,
Germany) [20]; InTec® HCVEIA (InTecProducts Inc., Xiamen,China)
[21]; Livzon® Anti-HCV (Zhuhai Livzon Diagnostics Inc., Zhuhai,
China) [22]. All assays were used according to the manufacturers’
instructions [15–22].
3.2. Samples
Details of the samples tested by each center are shown in
Table 1. These included several commercially available serocon-
version panels as follows: PHV912, PHV919, PHV921 (SeraCare Life
Sciences Inc., Milford, USA); HCV6212, HCV6224, and HCV 9058
(ZeptoMetrix Corporation, Buffalo, USA) (all composed of sera col-
lected from the USA).
Serum samples provided by each center (Table 1) were tested
with the Elecsys® Anti-HCV II assay and other center speciﬁc com-
parator assays to determine assay sensitivity and speciﬁcity. These
samples were received by the respective laboratory with a request
for HCV testing and were routine hospital samples sent for screen-
ing. The samples included those from patients on dialysis and with
thalassemia, as well as those positive for potentially cross-reacting
factors such as hepatitis B virus, hepatitis A/E virus, rheumatoid
factor, human immunodeﬁciency virus (HIV), systemic lupus ery-
thematosus and autoimmune hepatitis (Table 1).
3.3. Methods and analyses
Results for the Elecsys® Anti-HCV II assay were expressed as a
signal to cut-off (s/co) ratio; a s/co ratio<0.9 indicated a negative
result while a s/co ratio ≥1.0 was positive. A s/co ratio between 0.9
and <1.0 was considered to fall into a gray zone and these sam-
ples were considered positive for calculations within this study
[15]. Results obtained fromthe comparator assayswere interpreted
according to the information provided by themanufacturer; results
that fell into the gray zone given for comparator assays were also
considered to be positive [16–22].
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Table 1
Comparator assays and platform for the Elecsys® test used by each of the study centers.
Center Comparator assays Platform for the
Elecsys®
Anti-HCV II assay
Veriﬁcation method Sample type or source Number of
conﬁrmed positive
samples/total
samples tested
(positivity)
Chang Gung Memorial
Hospital, Taiwan ROC
ARCHITECTTM
Anti-HCV
MODULAR®
ANALYTICS E170
RecomLine HCV IgG
(Mikrogen, Neuried,
Germany)
Seroconversion panels
PHV912, HCV6212,
HCV6224, HCV9058
2,028 routine samples
175
/2028 (8.6%)
West China Hospital of
Sichuan University,
China
Elecsys® Anti-HCV;
InTec® HCV EIA;
Livzon® Anti-HCV
MODULAR®
ANALYTICS E170
recomLine HCV IgG PHV912, HCV6212,
HCV6224, HCV9058
1,044 routine samples
443 potentially
cross-reacting samples
8
/1044 (0.8%)
Chulalongkorn
University, Thailand
ARCHITECTTM
Anti-HCV
cobas e 411 HCV Blot 3.0 (MP
Biomedicals, Santa Ana
USA)
PHV912, PHV919,
PHV921, HCV6212
1,029 routine samples
36
/1029 (3.5%)
Peking University
People’s Hospital,
China
ARCHITECTTM
Anti-HCV; Vitros® ECi
Anti-HCV
MODULAR®
ANALYTICS E170
recomLine HCV IgG PHV912, HCV6212,
HCV6224, HCV9058
830 routine samples
17
/830 (2.0%)
Inje University Sanggye
Paik Hospital, South
Korea
ADVIA Centaur® HCV MODULAR®
ANALYTICS E170
HCV Blot 3.0 PHV912, HCV6212,
HCV6224, HCV9058
700 routine samples
5
/700 (0.7%)
Royal Prince Alfred
Hospital, Australia
Elecsys® Anti-HCV;
ARCHITECTTM
Anti-HCV
cobas e 602 HCV Blot 3.0; Vitros®
ECi Anti-HCV
PHV912, PHV919,
PHV921, HCV6212
572 routine samples
30
/572 (5.2%)
Hospital Ampang,
Malaysia
Vitros® ECi Anti-HCV;
Serodia®-HCV Particle
Agglutination
cobas e 411 Inno-LIATM HCV score
(Innogenetics, Ghent,
Belgium);
Serodia®-HCV Particle
Agglutination
PHV912, HCV6212,
HCV6224, HCV9058
528 routine samples
214 samples from
dialysis and
thalassemia patients
36
/528 (6.8%)
Prodia Clinical
Laboratory,
Indonesia
ADVIA Centaur® HCV cobas e 601 recomLine HCV IgG PHV912, HCV6212,
HCV6224, HCV9058
500 routine samples
14
/500 (2.8%)
Xin Hua Hospital, China Vitros® ECi Anti-HCV cobas e 601 recomLine HCV IgG PHV912, PHV919,
PHV921, HCV6212
495 routine samples
1
/495 (0.2%)
If the results using two or more assays to test the same sample
were concordant and the s/co ratio for both assayswas ≥5 the sam-
ple was deemed to be positive and veriﬁcation was not required.
Discrepant samples and samples with concordant positive results
but a s/co ratio <5 were subject to additional conﬁrmatory test-
ing using a third immunoassay and/or an HCV immunoblot. The
veriﬁcation methods are shown in Table 1.
Seroconversion panelswere used to assess howearly each assay
could detect infection. Comparisons of seroconversion sensitivity
were made by calculating the time at which the anti-HCV assays
detected the sample as being positive compared with the HCV RNA
test result; the positive nucleic acid test result was considered as
day 0.
The assay sensitivity and speciﬁcity were determined using
the daily routine samples. All HCV immunoblot-positive samples
were deemed to represent positive samples and were included in
the sensitivity calculations. Similarly, HCV immunoblot-negative
samples were considered negative and included in the speciﬁcity
calculation while HCV immunoblot-indeterminate samples were
excluded.
4. Results
4.1. Early detection sensitivity
The Elecsys® Anti-HCV II assay was more sensitive in recogniz-
ing early HCV infection than the comparator assays (Table 2 and
Fig. 1). The assay detected acute HCV infection earlier on average
than the comparator assays, including the ARCHITECTTM Anti-HCV
assay, for the panels tested.
4.2. Positivity of HCV infection and assay sensitivity
Of the 7,726 routine samples tested, 322 were identiﬁed as pos-
itive resulting in an overall positivity of HCV infection of 4.2%.
The positivity determined at the individual centers is shown in
Table 1. The Elecsys® Anti-HCV II (n=322), Elecsys® Anti-HCV
(n=38), Vitros® ECi Anti-HCV (n=54), and ADVIA Centaur® HCV
(n=19) assays all had a sensitivity of 100%. However, false-negative
results were observed with the ARCHITECTTM Anti-HCV (sensitiv-
ity 251/258 [97.3%]), InTec® HCV EIA (sensitivity 7/8 [87.5%]), and
Livzon® Anti-HCV (sensitivity 7/8 [87.5%]) assays. Statistical signif-
icance cannot bedemonstrated for these results due to thedifferent
number of samples tested with each assay. Twenty-nine samples
were excluded from the sensitivity calculations due to indetermi-
nate HCV immunoblot results.
4.3. Speciﬁcity
The overall speciﬁcity of the Elecsys® Anti-HCV II assay using
the routine samples was 99.66% and was comparable to, or bet-
ter than, the speciﬁcity of the other assays tested. Using a lower
total number of samples, the overall speciﬁcity of the compara-
tor assays varied from 98.98% (Elecsys® Anti-HCV; n=1,616) to
100% (InTec® HCV EIA; n=1,044). These data are shown in Table 3
along with the speciﬁcity data from the individual centers. The
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Serodia®-HCV Particle Agglutination assay was not used to test
routine samples.
The speciﬁcity of the Elecsys® Anti-HCV II assaywasnot affected
by potentially cross-reacting factors and was found to be 100%
(98.28–100%) in samples from 214 patients with thalassemia or
undergoing dialysis compared with 96.23% (92.70–98.36%) for the
Vitros® ECi Anti-HCV assay (eight false-positive results). Similarly,
the speciﬁcity of the Elecsys® Anti-HCV II assay was determined
to be 99.50% (98.22–99.94%) in 443 patients with other poten-
tially cross-reacting factors compared with 99.50% (98.22–99.94%)
for the Elecsys® Anti-HCV assay, 99.75% (98.63–99.99%) for the
InTec® HCV EIA and 100% (99.09–100%) for the Livzon® Anti-HCV
assay.
5. Discussion
This study demonstrates that the Elecsys® Anti-HCV II assay
has the sensitivity (100%) and speciﬁcity (99.66%) in samples from
Asian Paciﬁc populations to support its use as a routine screen-
ing method in the region. Furthermore, the seroconversion panel
results show that the Elecsys® Anti-HCV II assay detects infection
sooner than the comparator assays.
In the multicenter CE study, the Elecsys® Anti-HCV II assay
detected infection on average 3.8 days sooner than the previous
version of the test (Elecsys® Anti-HCV) [14]. The results obtained
here demonstrate a greater potential sensitivity as the Elecsys®
Anti-HCV II assay detected seroconversion a mean of 6 days before
the Elecsys® Anti-HCV assay and soon after the HCV RNA test.
Hence, the assay technology (double-antigen sandwich), use of
polypeptides and recombinant antigens, and unique antigen com-
bination appear to enhance the sensitivity for early detection of
infection as discussed previously [23]. Of note, the InTec® HCV EIA
andLivzon® Anti-HCVassays,whicharenotgenerally considered to
be state-of-the-art assays, were the least sensitive for early detec-
tion anddid not detect infection untilmore than12days on average
after the ARCHITECTTM Anti-HCV assay.
The prevalence of HCV in the Asian Paciﬁc region varies widely
[3–6] and is reﬂected by the HCV positivity found at the participat-
ing sites, which ranged from 0.2% to 8.6%. However, as the samples
tested in this study were not randomly selected (but sent with
a speciﬁc request for HCV testing) the results cannot be used to
generate prevalence estimates.
The sensitivity of the Elecsys® Anti-HCV II assay in samples from
Asian Paciﬁc populations was found to be 100%. This value com-
pares favorably with previously reported sensitivities for the assay
(also 100% [14,15,23,24]) and is similar or superior to that of the
other assays tested within this and other studies: ARCHITECTTM
Anti-HCV, 94.44–100% [14,23,25,26]; Elecsys® Anti-HCV, 100%
[14,24–26]; Vitros® ECi Anti-HCV, 99.5%–100% [23,24,26,27]; and
ADVIA Centaur® HCV, 97.5–100% [14,25,28]. The InTec® HCV EIA
and Livzon® Anti-HCV assays were the least sensitive (87.5% for
each). It is important to note that some of the studies mentioned
above were conducted using samples from European populations
[14,25,28] and several used fresh sera from blood donors as well
routine unselected clinical samples or preselected sera with low
positive anti-HCV results [14,23,25].
Given the high variability of HCV it is important that diagnos-
tic assays detect infection regardless of the genotype and subtype.
Several of the previous studies have investigated the sensitivity of
the assay for detecting individual HCV genotypes by genotyping
samples from patients known to be HCV positive prior to testing
[14,23]. For example, Esteban and colleagues speciﬁcally looked
at genotypes 1–6 [14] and Yang and colleagues investigated 203
samples with conﬁrmed genotypes 1b, 2a, 3a, 3b and 6a, which
are endemic to China [23]. Although in this study samples positive
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(A)
(B)
(C)
Fig. 1. Selected results from seroconversion panel testing for early detection of infection. Due to the fact that the seroconversion panel data did not reveal any differences
from site-to-site for one speciﬁc assay, the data shown here are from a single center, representative of all the centers. A, panel HCV9058; B, panel HCV6224; C, panel HCV6212
NEG=negative; POS=positive; indet = indeterminate; s/co = signal/cut-off ratio.
for known genotypes were not tested, a large number of routine
clinical samples were assessed. These are likely to represent the
genotypes and subtypesmost prevalent in the region (suchas geno-
types 1b, 3 and 6a) [29] and all of these samples were correctly
identiﬁed as positive by the Elecsys® Anti-HCV II assay. Further-
more, we found the speciﬁcity of the Elecsys® Anti-HCV II assay
to be similar or superior to that of the other assays tested. Com-
bining our ﬁndings with those previously published, the speciﬁcity
is 99.64–99.66% for the Elecsys® Anti-HCV II [14,23], 98.8–99.76%
for the ARCHITECTTM Anti-HCV [14,23,25,26], 99.1–99.9% for the
Elecsys® Anti-HCV [14,24,25], 96.5–99.76% for theVitros® ECi Anti-
HCV [23–27,30] and 99.05–99.9% for the ADVIA Centaur® HCV
assay [25,28]. In addition, our results conﬁrm those of the mul-
ticenter CE study and demonstrate that the assay is suitable for use
in a variety of populations [14].
According to the Asian Paciﬁc Association for the Study of the
Liver guidelines, samples that are anti-HCV positive should ideally
be retested using a second assay with high speciﬁcity. However,
this increases the cost of testing and hence may not be possible.
As an alternative, the guidelines state that: ‘Samples reactive in an
approved single EIA can be reported as anti-HCV positive provided
the signal to cut-off ratio is sufﬁcientlyhigh tobepredictiveof a true
positive’ [8]. In this study samples did not need to be veriﬁed if the
results using twoormore assays to test the samesampleswere con-
cordant and the s/co ratio for both assays was ≥5; this was to avoid
extensive and expensive conﬁrmation by alternative techniques. In
total 307 samplesdidnot require veriﬁcation.While a thresholdhas
not been established for this new version of the assay, a study of
the Elecsys® Anti-HCV assay suggested a s/co ratio≥150was highly
predictive (≥95%) of infection status, as determined by supplemen-
tal recombinant immunoblot assay testing, and could avoid 90% of
supplementary testing [31]. Analysis of previous results using the
Elecsys® Anti-HCV II assay suggest that a s/co ratio of 20.0 is predic-
tive of a truepositive result ≥95%of the time [23]. However, further
investigations are required before this value can be adopted [23].
Interestingly,Wuet al. investigated the appropriate s/co thresholds
for several assays currently used in China and determined them to
be 12.0 for the InTec® assay and 5.0 for the ARCHITECTTM assay
[32]. These results conﬁrm earlier ﬁndings suggesting a s/co ratio
of ≥8.6 for the InTec® assay predicted 96.1% of true positive results
[33].
In conclusion, this study conﬁrms the very good speciﬁcity and
superior sensitivity of the Elecsys® Anti-HCV II assay and shows
that it shortens the diagnostic window between infection and the
detection of antibodies, compared with established routine meth-
ods.
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Table 3
Assay speciﬁcity determined using routine hospital samples.a
Center (number of samples) Speciﬁcity (%) with 95% conﬁdence intervals (2-sided)
Elecsys®Anti-HCV II Elecsys®Anti-HCV ARCHITECTTMAnti-HCV Vitros®ECi Anti-HCV ADVIA Centaur®HCV InTec® HCV EIA Livzon®Anti-HCV
Chang Gung Memorial Hospital, 99.73 99.84
Taiwan ROC (n=2,028) 99.37–99.91 99.53–99.97
RR≥1 s/co 184 177
RR≥0.9 s/co–<1.0 s/co 0 N/A
Immunoblot positiveb,c 12/21 6/14
Immunoblot indeterminatec 4/21 5/14
West China Hospital of Sichuan 99.81 98.64 100 99.81
University, China (n=1,044) 99.30–99.98 97.73–99.25 99.64–100 99.30–99.98
RR≥1 s/co 14 27 9 12
RR≥0.9 s/co–<1.0 s/co 0 0 N/A N/A
Immunoblot positived 1/7 1/20 0/2 0/5
Immunoblot indeterminate 4/7 5/20 2/2 3/5
Chulalongkorn University, Thailand 99.80 100
(n=1,029) 99.27–99.98 99.63–100
RR≥1 s/coe 39 37
RR≥0.9 s/co–<1.0 s/co 0 N/A
Immunoblot positivee,f 2/5 2/3
Immunoblot indeterminatee 1/5 1/3
Peking University People’s 99.63 99.38 99.38
Hospital, China (n=830) 98.92–99.92 98.57–99.80 98.57–99.80
RR≥1 s/co 21 25 24
RR≥0.9 s/co–<1.0 s/co 0 0 N/A
Immunoblot positiveg 2/6 2/10 1/9
Immunoblot indeterminate 1/6 3/10 3/9
Inje University Sanggye Paik
Hospital, South Korea (n=700)
99.86 100
99.20–100 99.47–100
RR≥1 s/co 6 5
RR≥0.9 s/co–<1.0 s/co 0 0
Immunoblot positiveh 0/1 0/0
Immunoblot indeterminate 0/1 0/0
Royal Prince Alfred Hospital, 99.26 99.63 99.63
Australia (n=572) 98.11–99.80 98.66–99.95 98.66–99.95
RR≥1 s/coi 37 35 33
RR≥0.9 s/co–<1.0 s/co 0 0 N/A
Immunoblot positivei 3/10 3/8 3/6
Immunoblot indeterminate 3/10 3/8 1/6
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Table 3 (Continued)
Center (number of samples) Speciﬁcity (%) with 95% conﬁdence intervals (2-sided)
Elecsys®Anti-HCV II Elecsys®Anti-HCV ARCHITECTTMAnti-HCV Vitros®ECi Anti-HCV ADVIA Centaur®HCV InTec® HCV EIA Livzon®Anti-HCV
Hospital Ampang, Malaysia 99.18 97.95
(n=528) 97.91–99.78 96.26–99.01
RR≥1 s/co 41 49
RR≥0.9 s/co–<1.0 s/co 0 1
Immunoblot positivej 0/5 0/14
Immunoblot indeterminate 1/5 4/14
Prodia Clinical Laboratory, 99.17 99.59
Indonesia (n=500) 97.89–99.77 98.51–99.95
RR≥1 s/co 21 16
RR≥0.9 s/co–<1.0 s/co 0 0
Immunoblot positivek 1/8 1/3
Immunoblot indeterminate 3/8 0/3
Xin Hua Hospital, China (n=495) 100 99.6
99.26–100 98.55–99.95
RR≥1 s/co 1 3
RR≥0.9 s/co–<1.0 s/co 0 0
Immunoblot positivel 0/0 0/2
Immunoblot indeterminate 0/0 0/2
Total number of samples 7,726 1,616 4,459 1,853 1,200 1,044 1,044
Overall speciﬁcity 99.66 98.98 99.76 99.05 99.83 100 99.81
99.50–99.78 98.35–99.42 99.56–99.89 98.49–99.45 99.39–99.98 99.64–100 99.30–99.98
N/A=not applicable; RR= repeatedly reactive; s/co = signal to cut-off.
a 29 samples gave an indeterminate HCV immunoblot result and were excluded from the speciﬁcity calculation.
b 161 samples detected as positive with both assays.
c 2 immunoblots not determined; counted as positive.
d 7 samples detected as positive with all four assays; sample indeterminate following veriﬁcation.
e 34 samples detected as positive with both assays.
f 1 sample indeterminate following veriﬁcation.
g 15 samples detected as positive with all three assays.
h 5 samples detected as positive with both assays.
i 27 samples detected as positive with all three assays.
j 36 samples detected as positive with both assays.
k 13 samples detected as positive with both assays.
l 1 sample detected as positive with both assays.
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